Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who answer TRUE to the following criteria may be eligible to participate in this study.~* Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT spread to the other parts of the body (metastases). Patients with lymph node involvement may be eligible if specified criteria is met.~* Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment~* Currently receiving treatment with surgical or medical castration~Exclusion Criteria:~Patients who answer TRUE to the following may NOT be eligible to participate in this study.~* Currently using opiate based pain killers for cancer related pain~* Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial~* Suffering from heart failure or had a myocardial infarction within last 6 months~* A history of epilepsy or seizures

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching Placebo
- ZD4054 (Type: EXPERIMENTAL): ZD4054 (Zibotentan)

Based on this trial design, predict the completion outcome and termination type (if applicable).